摘要
目的 检测急性髓性白血病 (AML)中CD34 ,bcl 2的表达 ,并评价其临床意义及CD34 ,bcl 2间可能存在的关系。方法 免疫细胞化学APAAP法。结果 CD34 、bcl 2表达与AML外周血WBC数。骨髓原始细胞比例、CUF L等临床特征无关 ;而继发性AMLCD34 水平显著高于原发性AML患者 (P <0 .0 5 ) ;但bcl 2水平在原发 ,继发AML中无差别。原发性AML中CD34 水平与化疗疗效无关 (P >0 .0 5 ) ;无论原发AML或AML中 ,bcl 2表达均与化疗耐药有关。结论 CD34 并非一个能独立耐药相关的因素 ,而bcl 2可以独立决定化疗反应 ;CD34 和bcl 2无相关性。
Objective To examine the differentiated antigen CD 34 and bcl-2 expression in 40 cases of acute myeloblastic leukemia(AML) and to evaluate their clinical significance.Methods Immunocytochemical APAAP assay was used.Results CD 34 and bcl-2 expression were independent of peripheral white blood cell,proportion of leukocytes in bone marrow nucleate cells and CFU-L.Higher expression of CD 34 was found in secondary AML than in primary AML (P<0.05),while expression of bcl-2 showed no difference.No significant correlation was found between CD 34 level and drug resistance in primary AML(P>0.05) but in primary AML or AML,bcl-2 is correlated with durg resistance.Conclusion It is bcl-2,not CD 34 ,that can independently predict chemotherapeutic response.No correlation is found between CD 34 and bcl-2 expression.
出处
《中国肿瘤临床与康复》
2001年第5期16-17,15,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
